Pheochromocytoma pathophysiology: Difference between revisions

Jump to navigation Jump to search
Line 19: Line 19:


==Genetics==
==Genetics==
Pheochromocytomas can be familial and  occur in patients with  [[multiple endocrine neoplasia]] (MEN 2 and MEN 3). Patients with Von Hippel Lindau ([[VHL]]) may also develop pheocromocytoma.<ref name="pmid24642075">{{cite journal| author=Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM| title=The genetic basis of pheochromocytoma and paraganglioma: implications for management. | journal=Urology | year= 2014 | volume= 83 | issue= 6 | pages= 1225-32 | pmid=24642075 | doi=10.1016/j.urology.2014.01.007 | pmc=4572836 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24642075  }}</ref> It is autosomal dominant inheritance and has two pathways of tumor pathogenesis. Cluster 1 tumorsare  noradrenergic. Cluster 2 tumors are adrenergic.<ref name="pmid23933153">{{cite journal| author=King KS, Pacak K| title=Familial pheochromocytomas and paragangliomas. | journal=Mol Cell Endocrinol | year= 2014 | volume= 386 | issue= 1-2 | pages= 92-100 | pmid=23933153 | doi=10.1016/j.mce.2013.07.032 | pmc=3917973 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23933153  }}</ref>
* Pheochromocytomas can be familial and  occur in patients with  [[multiple endocrine neoplasia]] (MEN 2 and MEN 3).
* Patients with Von Hippel Lindau ([[VHL]]) may also develop pheocromocytoma.<ref name="pmid24642075">{{cite journal| author=Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM| title=The genetic basis of pheochromocytoma and paraganglioma: implications for management. | journal=Urology | year= 2014 | volume= 83 | issue= 6 | pages= 1225-32 | pmid=24642075 | doi=10.1016/j.urology.2014.01.007 | pmc=4572836 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24642075  }}</ref>  
* It is autosomal dominant inheritance and has two pathways of tumor pathogenesis. Cluster 1 tumorsare  noradrenergic. Cluster 2 tumors are adrenergic.<ref name="pmid23933153">{{cite journal| author=King KS, Pacak K| title=Familial pheochromocytomas and paragangliomas. | journal=Mol Cell Endocrinol | year= 2014 | volume= 386 | issue= 1-2 | pages= 92-100 | pmid=23933153 | doi=10.1016/j.mce.2013.07.032 | pmc=3917973 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23933153  }}</ref>
{| class="wikitable"
{| class="wikitable"
!Cluster 1
!Cluster 1
Line 36: Line 38:


==Associated conditions==
==Associated conditions==
Pheochromocytoma can be part of other syndromes named Multiple endocrien neoplasia (MEN2) Which are autosomal dominant syndromes controlled by RET gene. Pheochromocytoma occurs in 50% of patients with MEN2 as follows:
* Pheochromocytoma can be part of other syndromes named Multiple endocrien neoplasia (MEN2) Which are autosomal dominant syndromes controlled by RET gene. Pheochromocytoma occurs in 50% of patients with MEN2 as follows:
{| class="wikitable"
{| class="wikitable"
!MEN1
!MEN1

Revision as of 19:31, 5 July 2017

Pheochromocytoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pheochromocytoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pheochromocytoma pathophysiology On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pheochromocytoma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pheochromocytoma pathophysiology

CDC on Pheochromocytoma pathophysiology

Pheochromocytoma pathophysiology in the news

Blogs on Pheochromocytoma pathophysiology

Directions to Hospitals Treating Pheochromocytoma

Risk calculators and risk factors for Pheochromocytoma pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]

Overview

Pheochromocytoma arise from chromaffin cells of the adrenal medulla.On gross pathology, pheochromocytoma has a multinodular and a multicentric pattern of growth. On microscopic histopathological analysis, nesting (Zellballen) pattern composed of well-defined clusters of tumor cells separated by fibrovascular stroma is a characteristic finding.it may be benign or malignant, familial origin(multiple endocrine neoplasia type 2) or sporadic one. Both of them have genetic origin depends on large number of genes: VHL, SDH, NF1, RET.

Pathophysiology

Pheochromocytoma arise from chromaffin cells of the adrenal medulla and sympathetic ganglia. Traditionally pheochromocytoma known as the "10% tumor":

  • Approximately 10% of patients have bilateral disease
  • Approximately 10% of tumors are malignant
  • Approximately 10% are located in chromaffin tissue outside of the adrenal gland, The most common extradrenal locations are the abdomen and thorax .
  • Approximately 10% occur in childhood
  • Approximately 10% are familial
  • Approximately 10% recur after being resected
  • Approximately 10% of patients do not have hypertension

Malignant and benign pheochromocytomas are the same; The only difference is the ability to spread locally and distant. [1]

Genetics

  • Pheochromocytomas can be familial and occur in patients with multiple endocrine neoplasia (MEN 2 and MEN 3).
  • Patients with Von Hippel Lindau (VHL) may also develop pheocromocytoma.[2]
  • It is autosomal dominant inheritance and has two pathways of tumor pathogenesis. Cluster 1 tumorsare noradrenergic. Cluster 2 tumors are adrenergic.[3]
Cluster 1 Cluster 2
  • Succinate dehydrogenase (SDH) subunit genes
  • Von Hippel-Lindau (VHL) disease
  • Fumarate hydratase gene mutations
  • Multiple endocrine neoplasia type 2A
  • Multiple endocrine neoplasia type 2B
  • Neurofibromatosis type 1 (NF1)

. Patients with the succinate dehydrogenase B mutations are likely to develop malignant disease.[4]

Associated conditions

  • Pheochromocytoma can be part of other syndromes named Multiple endocrien neoplasia (MEN2) Which are autosomal dominant syndromes controlled by RET gene. Pheochromocytoma occurs in 50% of patients with MEN2 as follows:
MEN1 MEN2
  • Medullary thyroid cancer,
  • Pheochromocytoma
  • Primary hyperparathyroidism
  • Medullary thyroid cancer
  • Pheochromocytoma
  • Mucosal neuromas
  • Marfanoid habitus

Gross Pathology

On gross pathology, A multinodular and multicentric pattern of growth of pheochromocytoma may be seen.

Microscopic Pathology

On microscopic pathology, Pheochromocytoma typically demonstrates a nesting (Zellballen) pattern on microscopy. This pattern is composed of well-defined clusters of tumor cells containing eosinophilic cytoplasm separated by fibrovascular stroma.

Videos

{{#ev:youtube|7yjxG3KmX98}}

References

  1. Goldstein RE, O'Neill JA, Holcomb GW, Morgan WM, Neblett WW, Oates JA; et al. (1999). "Clinical experience over 48 years with pheochromocytoma". Ann Surg. 229 (6): 755–64, discussion 764-6. PMC 1420821. PMID 10363888.
  2. Shuch B, Ricketts CJ, Metwalli AR, Pacak K, Linehan WM (2014). "The genetic basis of pheochromocytoma and paraganglioma: implications for management". Urology. 83 (6): 1225–32. doi:10.1016/j.urology.2014.01.007. PMC 4572836. PMID 24642075.
  3. King KS, Pacak K (2014). "Familial pheochromocytomas and paragangliomas". Mol Cell Endocrinol. 386 (1–2): 92–100. doi:10.1016/j.mce.2013.07.032. PMC 3917973. PMID 23933153.
  4. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M; et al. (2004). "Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations". JAMA. 292 (8): 943–51. doi:10.1001/jama.292.8.943. PMID 15328326.


Template:WikiDoc Sources